Results 21 to 30 of about 15,597 (227)

Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice

NeuroImage, 2021
Hallucinogenic agents have been proposed as potent antidepressants; this includes the serotonin (5-HT) receptor 2A agonist psilocybin. In human subjects, psilocybin alters functional connectivity (FC) within the default-mode network (DMN), a ...
Joanes Grandjean, David Buehlmann, Michaela Buerge, Hannes Sigrist, Erich Seifritz, Franz X. Vollenweider, Christopher R. Pryce, Markus Rudin   +7 more
doaj   +1 more source

Substance use in the club scene of Rome : a pilot study [PDF]

, 2014
Date of Acceptance: 28/08/2014 Copyright © 2014 Alessandro Emiliano Vento et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium ...
Acciavatti, Tiziano, Bonifaci, Ludovica, Carrus, Dario, Chillemi, Eleonora, Cinosi, Eduardo, Corazza, Ornella, di Giannantonio, Massimo, Lupi, Matteo, Martinotti, Giovanni, Santacroce, Rita, Schifano, Fabrizio, Vento, Alessandro   +11 more
core   +4 more sources

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Scientific Reports, 2023
Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health
Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross, Robin L. Carhart-Harris   +7 more
doaj   +1 more source

Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers [PDF]

, 2012
The serotonin-2A receptor (5-HT(2A)R) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients.
Geyer, M A, Kometer, M, Quednow, Boris B, Vollenweider, F X   +3 more
core   +1 more source

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

Pharmaceuticals, 2021
There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD).
Rene Zeiss, Maximilian Gahr, Heiko Graf
doaj   +1 more source

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences

Scientific Reports, 2023
Research into the use of psilocybin for the treatment of psychiatric disorders is a growing field. Nevertheless, robust brain–behavior relationships linking psilocybin-induced brain changes to subjective drug-induced effects have not been established ...
Nathalie M. Rieser, Ladina P. Gubser, Flora Moujaes, Patricia Duerler, Candace R. Lewis, Lars Michels, Franz X. Vollenweider, Katrin H. Preller   +7 more
doaj   +1 more source

The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines [PDF]

, 2018
Classic psychedelics are substances of paramount cultural and neuroscientific importance. A distinctive feature of psychedelic drugs is the wide range of potential subjective effects they can elicit, known to be deeply influenced by the internal state of
Erowid, Earth, Erowid, Fire, Martínez Vivot, Rocío, Pallavicini, Carla, Sanz, Camila, Tagliazucchi, Enzo Rodolfo, Zamberlan, Federico   +6 more
core   +2 more sources

"A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.

PLoS ONE, 2022
ObjectivesPeople with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin,
Meghan DellaCrosse, Mollie Pleet, Emma Morton, Amir Ashtari, Kimberly Sakai, Josh Woolley, Erin Michalak   +6 more
doaj   +1 more source

Adolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods. [PDF]

, 2018
One of the objectives of the Adolescent Brain Cognitive Development (ABCD) Study (https://abcdstudy.org/) is to establish a national longitudinal cohort of 9 and 10 year olds that will be followed for 10 years in order to prospectively study the risk and
Bartsch, Hauke, Conway, Kevin P, Feldstein Ewing, Sarah W, Goldstein, Rita Z, Gonzalez, Raul, Heitzeg, Mary, Lisdahl, Krista M, Nixon, Sara Jo, Sher, Kenneth J, Tapert, Susan   +9 more
core   +2 more sources

A proof-of concept randomized controlled trial to show that the antidepressant effect of psilocybin does not require a psychedelic experience: study protocol

European Psychiatry, 2023
Introduction During the last decade there has been a resurgence of interest on the use of psychedelics as novel treatments for mental disorders, including treatment-resistant depression (TRD). Psilocybin, the chemical component of “magic mushrooms”, has
M. I. Husain, D. M. Blumberger, D. J. Castle, S. M. Kloiber, A. Ortiz, J. D. Rosenblat, B. H. Mulsant   +6 more
doaj   +1 more source